Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRA 2°P - TIMI 50 of SCH 530348 in secondary prevention of atherothrombotic ischemic events
2006-002942-12Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, coronary arteriosclerosis, cerebrovascular disease and 1 more comparing SCH 530348 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary efficacy endpoint. Started Aug 2007; status: completed.
02
Drugs
vorapaxar
03
Conditions
atherosclerotic diseasecoronary arteriosclerosiscerebrovascular diseasearteriosclerosis obliterans
Beyond the preview
Go deeper on 2006-002942-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002942-12.